The rare genetic disease hereditary angioedema causes swelling in patients who have it. If swelling occurs near the airway, it can become life threatening. Currently, patients rely on intravenous or subcutaneous injections to manage the condition. Not only is treatment for this orphan disease expensive and unpleasant, but it is also unsuitable for prophylaxis, forcing patients to wait until an episode of swelling is already underway before seeking treatment.
Verseon is developing a treatment available as an oral pill. We are committed to serving people with unmet medical needs, even if the patient population is small.
Mortality rate in the first two decades of life for undiagnosed patients
Conventional treatment costs per patient
Reduction in average lifespan for those dying of complications from HAE
Estimated number of HAE patients worldwide
Estimated global HAE market